Crizotinib-associated Renal Cyst Formation in a Pediatric Patient With ALK+ Epithelioid Inflammatory Myofibroblastic Sarcoma

Urology. 2021 Mar:149:222-224. doi: 10.1016/j.urology.2020.08.032. Epub 2020 Sep 1.

Abstract

Background: Crizotinib is a first-generation tyrosine kinase inhibitor used for anaplastic lymphoma kinase (ALK) positive cancers. Simple and complex renal cyst formation is a rare complication of crizotinib use that has been reported previously in the adult population.

Case: We report a case of a right renal mass in a 17-year-old with ALK-positive epithelioid inflammatory myofibroblastic sarcoma treated with Crizotinib. After cessation of Crizotinib and initiating Alectenib, a second generation ALK inhibitor, the mass decreased in size and the patient remained asymptomatic without evidence of recurrence at three months of follow-up.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Crizotinib / adverse effects*
  • Crizotinib / therapeutic use
  • Humans
  • Kidney Diseases, Cystic / chemically induced*
  • Male
  • Neoplasms, Muscle Tissue / chemistry
  • Neoplasms, Muscle Tissue / drug therapy
  • Receptor Protein-Tyrosine Kinases / analysis
  • Sarcoma / chemistry
  • Sarcoma / drug therapy

Substances

  • Antineoplastic Agents
  • Crizotinib
  • Receptor Protein-Tyrosine Kinases